.

Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection

LAUR Repository

Show simple item record

dc.contributor.author Al Faran, Abdulrahman
dc.contributor.author Mousa, Ahmad
dc.contributor.author Al Shamsi, Hanan
dc.contributor.author Al Gaeed, Abdulrahman
dc.contributor.author Ghazi, Nicola G.
dc.date.accessioned 2019-06-14T06:39:47Z
dc.date.available 2019-06-14T06:39:47Z
dc.date.copyright 2014 en_US
dc.identifier.issn 1539-2864 en_US
dc.identifier.uri http://hdl.handle.net/10725/10811
dc.description.abstract Purpose: To study prognostic spectral domain optical coherence tomography parameters in diabetic cystoid macular edema after anti–vascular endothelial growth factor therapy. Methods: Retrospective cohort study included 49 eyes with the new onset diabetic cystoid macular edema that had to have a macular spectral domain optical coherence tomography and fluorescein angiography at presentation. The baseline optical coherence tomography scans were analyzed for variables indicative of the extent of retinal involvement by the cystoid change and its location about the center. Univariate and multivariate analyses were performed comparing the optical coherence tomography findings between the two groups of eyes: the “No improvement” and the “Improvement” groups, based on at least two Snellen lines improvement after treatment. Results: There were 30 and 19 eyes in the No improvement and Improvement groups, respectively. In the univariate analysis, the baseline optical coherence tomography parameters associated with visual improvement included the photoreceptor inner segments thickness centrally (P = 0.009) and within the central 1-mm subfield (P < 0.0001), and the presence of bridging retinal processes centrally (P = 0.004). Multivariate analysis showed both presence and central location of bridging retinal processes within the central 1-mm subfield to be significantly associated with visual improvement (P = 0.041 and 0.005, respectively), with an odds ratio of 13.4 (95% confidence interval, 1.336–636.18; P = 0.010) for their central location. Conclusion: In diabetic cystoid macular edema, visual improvement after anti–vascular endothelial growth factor therapy is more likely to occur in eyes with residual central retinal processes on baseline macular spectral domain optical coherence tomography. This finding may be helpful in patient counseling, case selection, and clinical trial planning. en_US
dc.language.iso en en_US
dc.title Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201000154 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Retina en_US
dc.journal.volume 34 en_US
dc.journal.issue 6 en_US
dc.article.pages 1208-1215 en_US
dc.identifier.doi https://doi.org/10.1097/IAE.0000000000000059 en_US
dc.identifier.ctation Al Faran, A., Mousa, A., Al Shamsi, H., Al Gaeed, A., & Ghazi, N. G. (2014). Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection. Retina, 34(6), 1208-1215. en_US
dc.author.email nicola.ghazi@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://oce.ovid.com/article/00006982-201406000-00024/HTML en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account